tioconazole - Profile

What are the generic drug sources for tioconazole and what is the scope of freedom to operate?

Tioconazole is the generic ingredient in three branded drugs marketed by Pfizer, Perrigo, and Combe, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for tioconazole

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for tioconazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TZ-3	tioconazole	CREAM;TOPICAL	018682-001	Feb 18, 1983		DISCN	No	No
Perrigo	TIOCONAZOLE	tioconazole	OINTMENT;VAGINAL	075915-001	Nov 21, 2001		OTC	No	No
Combe	VAGISTAT-1	tioconazole	OINTMENT;VAGINAL	020676-001	Feb 11, 1997		OTC	Yes	Yes

Expired US Patents for tioconazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TZ-3	tioconazole	CREAM;TOPICAL	018682-001	Feb 18, 1983
Pfizer	TZ-3	tioconazole	CREAM;TOPICAL	018682-001	Feb 18, 1983

Tioconazole: Patent Landscape and Market Fundamentals for Investment Analysis

Last updated: February 19, 2026

Tioconazole, an imidazole antifungal agent, presents an investment scenario driven by its established efficacy against dermatophytic and yeast infections and the ongoing patent expiration landscape. This analysis focuses on its core patent protection, generic market entry, and therapeutic market positioning to inform R&D and investment decisions.

What is Tioconazole?

Tioconazole is a broad-spectrum antifungal medication. It functions by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately cell death. It is primarily used topically for the treatment of fungal infections of the skin and vagina.

What are Tioconazole's Primary Therapeutic Indications?

Tioconazole's therapeutic utility is concentrated in topical antifungal applications.

• Dermatophytosis: This category includes infections such as athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). These are common superficial fungal infections of the skin caused by dermatophytes.
• Vulvovaginal Candidiasis (Yeast Infections): Tioconazole is effective against Candida albicans and other Candida species responsible for vaginal yeast infections.

What is the Core Patent Protection for Tioconazole?

The foundational patent for tioconazole was initially filed by Pfizer Inc. The primary patent covering tioconazole as a chemical compound and its use in treating fungal infections has long since expired in major markets.

• Key Patent Expiration Dates:

  • United States: The principal patent for tioconazole expired in the early 2000s. Specific patent numbers and their expiration dates are publicly accessible through the U.S. Patent and Trademark Office (USPTO) database. For example, U.S. Patent No. 3,714,271, which broadly claims imidazole derivatives including tioconazole, expired in 1990.
  • Europe: Similar patent expiries have occurred across European Union member states, generally aligning with the timeframe of U.S. expirations for the core compound.
  • Other Markets: Patent protection in other global markets has also largely lapsed.

• Formulation and Method of Use Patents: While the compound patent is expired, manufacturers might hold patents on specific formulations (e.g., novel creams, ointments, or vaginal suppositories with improved delivery or stability) or novel methods of use. However, these are typically secondary and more limited in scope compared to the original compound patent. Generic manufacturers typically circumvent these by developing bioequivalent formulations that do not infringe on active patent claims.

What is Tioconazole's Market Status and Generic Competition?

The expiration of its primary patents has led to a robust generic market for tioconazole.

• Generic Availability: Tioconazole is widely available as a generic medication in various topical formulations, including creams, ointments, and vaginal suppositories.
• Key Generic Manufacturers: Numerous pharmaceutical companies manufacture and market generic tioconazole. Notable players in the generic antifungal market include but are not limited to:
  • Apotex Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V. (now part of Viatris Inc.)
  • Sandoz (a division of Novartis AG)
  • Perrigo Company plc
• Market Entry Timeline: Generic entry began in earnest following the expiration of key patents in the early 2000s, leading to significant price erosion for the active pharmaceutical ingredient (API) and finished dosage forms.
• Pricing: Due to extensive generic competition, the price of tioconazole is significantly lower than its branded counterpart (e.g., Vagistat-1, which was a prominent brand). This price point is a critical factor for market penetration and volume-based sales.

How is Tioconazole Positioned in the Antifungal Market?

Tioconazole competes within a crowded topical antifungal market, facing both azole and non-azole alternatives.

• Competitive Set (Azole Antifungals):
  • Clotrimazole: Widely available, generic, similar spectrum of activity.
  • Miconazole: Also generic, common in OTC and prescription topical formulations.
  • Ketoconazole: Available in prescription shampoos and topical creams, some formulations face specific safety concerns or restrictions.
  • Econazole: Another azole with a comparable efficacy profile.
• Competitive Set (Non-Azole Antifungals):
  • Terbinafine: Highly effective, particularly for dermatophytes, often considered a first-line treatment for tinea pedis. Available generically.
  • Naftifine: Another allylamine antifungal.
  • Tolnaftate: Primarily used for dermatophytosis, often available OTC.
• Therapeutic Overlap: Tioconazole's spectrum covers common superficial fungal infections, placing it in direct competition with other broad-spectrum topical antifungals. Its efficacy against Candida species also positions it against other vaginal antifungal treatments.
• Dosing and Formulation Advantages/Disadvantages: The availability of single-dose vaginal suppositories for tioconazole (e.g., 6.5% strength) offers a convenience factor for patients experiencing vulvovaginal candidiasis, potentially differentiating it from multi-day treatments. However, for dermatophytosis, it competes with other topical agents where duration of treatment and penetration can vary.

What are the Regulatory Aspects and Manufacturing Considerations?

Regulatory approval and manufacturing efficiency are crucial for any pharmaceutical product, including tioconazole.

• Regulatory Status: Tioconazole is approved by major regulatory bodies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • FDA Approvals: Tioconazole has approved indications for topical use in treating fungal infections.
  • European Approvals: Similar approvals exist across EU member states.
• Manufacturing and API Sourcing: The active pharmaceutical ingredient (API) for tioconazole is manufactured by several chemical synthesis companies globally, particularly in India and China. The availability of multiple API suppliers contributes to competitive pricing and supply chain resilience for generic manufacturers.
• Good Manufacturing Practices (GMP): Manufacturers of both API and finished dosage forms must adhere to strict GMP standards to ensure product quality, safety, and efficacy. Regulatory bodies conduct inspections to enforce these standards.
• Quality Control: Rigorous quality control measures are in place at all stages of production, from raw material testing to final product release, to ensure compliance with pharmacopeial standards.

What is the Market Size and Growth Potential for Topical Antifungals?

The market for topical antifungal treatments is substantial and influenced by several factors.

• Market Size: The global topical antifungal market is valued in the billions of U.S. dollars. Precise figures vary by market research reports, but consistent growth is observed. For instance, the global topical antifungal market was estimated to be worth over USD 8 billion in 2023 and is projected to grow at a CAGR of approximately 5-7% [1].
• Growth Drivers:
  • Rising Incidence of Fungal Infections: Factors such as increased global travel, immune suppression in certain patient populations (e.g., HIV/AIDS, chemotherapy patients), and changes in hygiene practices contribute to a higher prevalence of fungal infections.
  • Aging Population: Older individuals are more susceptible to various infections, including fungal ones.
  • Growing Awareness and Diagnosis: Increased patient and physician awareness of fungal infections leads to better diagnosis and treatment.
  • Over-the-Counter (OTC) Availability: Many topical antifungals, including some tioconazole formulations, are available OTC, increasing accessibility.
  • Development of New Formulations: Innovations in drug delivery and formulation can enhance efficacy and patient compliance, driving market demand.
• Market Challenges:
  • Intense Generic Competition: The presence of numerous generic products leads to price wars and limits significant price increases.
  • Development of Resistance: While less common with topical agents compared to systemic antifungals, the potential for resistance development exists.
  • Advancements in Systemic Treatments: For more severe or recalcitrant infections, systemic antifungal therapies are sometimes preferred, potentially limiting the market for topical agents in those specific cases.

Investment Considerations for Tioconazole

An investment in tioconazole-related products would primarily focus on generic manufacturing, API production, or potentially niche formulation development.

• Generic Manufacturing: Companies with efficient manufacturing processes, established distribution networks, and strong cost management can achieve profitability in the generic tioconazole market. Success hinges on high-volume sales and competitive pricing.
• API Production: Suppliers of tioconazole API can benefit from supplying multiple generic manufacturers. Profitability depends on production scale, cost of raw materials, and quality compliance.
• Formulation Innovation: While the core compound patent is expired, there may be opportunities for companies to develop novel, value-added formulations of tioconazole. This could include improved delivery systems, enhanced stability, combination products, or formulations targeting specific underserved patient populations. Such innovation would require new patent protection for the formulation itself.
• Market Dynamics: Investment decisions should consider the competitive intensity, pricing pressures, and the overall growth trajectory of the topical antifungal market. Diversification within the broader antifungal therapeutic class or adjacent dermatological areas might mitigate risks associated with reliance on a single, off-patent molecule.
• Regulatory Compliance: Maintaining robust quality systems and navigating evolving regulatory requirements are essential for sustained market access and investor confidence.

Key Takeaways

Tioconazole's investment profile is characterized by its established efficacy in treating common fungal infections and its mature, genericized market. The core compound patents have expired, leading to intense competition among numerous generic manufacturers. While the market for topical antifungals continues to grow, driven by increasing infection rates and patient awareness, pricing pressures are significant. Opportunities for investment lie primarily in efficient generic manufacturing, API supply, or potentially in the development of novel, patentable formulations that offer distinct advantages over existing generic options.

FAQs

1. Are there any active patents for tioconazole that could impact generic entry? The primary patents covering tioconazole as a chemical entity have expired. However, secondary patents may exist for specific novel formulations or manufacturing processes. Companies entering the market must conduct thorough freedom-to-operate analyses to ensure they do not infringe on any currently active, valid patents.

2. What is the primary competitive advantage of tioconazole against other topical antifungals? Tioconazole's competitive advantage lies in its broad-spectrum efficacy against common dermatophytes and yeasts, coupled with the availability of convenient single-dose vaginal formulations for vulvovaginal candidiasis. Its generic status also ensures cost-effectiveness.

3. What is the typical pricing structure for generic tioconazole products? Due to significant generic competition, tioconazole products are priced competitively. The price per unit is substantially lower than branded equivalents and varies based on dosage strength, formulation type (cream, ointment, suppository), and the specific manufacturer and distributor.

4. What are the key manufacturing challenges for tioconazole API and finished products? Key challenges include maintaining consistent API purity and quality to meet pharmacopeial standards, managing raw material costs, ensuring compliance with evolving Good Manufacturing Practices (GMP) regulations, and optimizing production processes for cost-efficiency to remain competitive in the generic market.

5. Beyond common fungal infections, are there any emerging or off-label uses for tioconazole that could represent future market growth? While tioconazole is well-established for its primary indications, research into potential new uses or enhanced efficacy in specific resistant strains is ongoing. However, significant clinical development and regulatory hurdles would be required for any new therapeutic indications or substantial expansion into off-label uses. The current market primarily relies on its approved uses.

Citations

[1] Grand View Research. (2024). Topical Antifungal Market Size, Share & Trends Analysis Report By Product (Azole Antifungals, Echinocandins, Allylamines, Polyenes, Others), By Application (Dermatophytosis, Candidiasis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2024 – 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/topical-antifungal-market